1. Home
  2. PLRX
  3. PLRX News

Latest Pliant Therapeutics Inc. (PLRX) News on November 8, 2025

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
PLRX

GlobeNewswire

2 days ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

3 Promising Penny Stocks With Market Caps Under $500M
PLRX

Simply Wall St.

22 days ago

3 Promising Penny Stocks With Market Caps Under $500M

PLRX

MT Newswires

a month ago

Pliant Therapeutics Shares Fall After JPMorgan Downgrade

Align downgraded, NetEase upgraded: Wall Street's top analyst calls
PLRX

The Fly

a month ago

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

PLRX

MT Newswires

a month ago

JPMorgan Downgrades Pliant Therapeutics to Underweight From Neutral

Penny Stocks To Watch With Market Caps Under $700M
PLRX

Simply Wall St.

2 months ago

Penny Stocks To Watch With Market Caps Under $700M

Pliant halts bexotegrast development for IPF after trial results
PLRX

Clinical Trials Arena

4 months ago

Pliant halts bexotegrast development for IPF after trial results

Pliant Therapeutics Provides Update on BEACON-IPF
PLRX

GlobeNewswire

4 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
PLRX

GlobeNewswire

6 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
PLRX

GlobeNewswire

6 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant cuts workforce by 45% following lung trial termination
PLRX

Clinical Trials Arena

6 months ago

Pliant cuts workforce by 45% following lung trial termination

PLRX

MT Newswires

6 months ago

Pliant Therapeutics to lay off 45% of Workforce in Restructuring Move

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma
PLRX

BioPharma Dive

6 months ago

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
PLRX

GlobeNewswire

6 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know
PLRX

Zacks

7 months ago

PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
PLRX

GlobeNewswire

7 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
PLRX

Zacks

7 months ago

PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know

PLRX

MT Newswires

8 months ago

Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
PLRX

GlobeNewswire

8 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
PLRX

BioPharma Dive

8 months ago

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

PLRX

MT Newswires

8 months ago

Pliant Therapeutics Signs Shareholder Rights Agreement

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
PLRX

GlobeNewswire

8 months ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

PLRX

MT Newswires

8 months ago

Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32

PLRX

MT Newswires

8 months ago

Needham Downgrades Pliant Therapeutics to Hold From Buy

Pliant Therapeutics stock tumbles amid IPF trial cancellation
PLRX

Clinical Trials Arena

8 months ago

Pliant Therapeutics stock tumbles amid IPF trial cancellation

PLRX

MT Newswires

8 months ago

RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data
PLRX

BioPharma Dive

8 months ago

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
PLRX

GlobeNewswire

8 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

PLRX

MT Newswires

8 months ago

Sector Update: Health Care Stocks Rise Monday Afternoon

PLRX

MT Newswires

8 months ago

Pliant Therapeutics Ends Phase 2b Trial of Bexotegrast for Idiopathic Pulmonary Fibrosis; Shares Fall

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
PLRX

GlobeNewswire

8 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks
PLRX

Simply Wall St.

9 months ago

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy
PLRX

Zacks

9 months ago

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

PLRX

MT Newswires

9 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

PLRX

MT Newswires

9 months ago

Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
PLRX

BioPharma Dive

9 months ago

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
PLRX

GlobeNewswire

9 months ago

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan
PLRX

TipRanks

9 months ago

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan

PLRX

MT Newswires

9 months ago

Sector Update: Health Care Stocks Retreat Monday Afternoon

PLRX

MT Newswires

9 months ago

Top Midday Decliners

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive
PLRX

GuruFocus.com

9 months ago

Pliant Therapeutics Pauses Enrollment in BEACON-IPF Trial, Shares Take Steep Dive

PLRX

MT Newswires

9 months ago

Pliant Therapeutics Shares Tumble Amid Analyst Downgrades Following Study Suspension

PLRX

MT Newswires

9 months ago

Sector Update: Health Care Stocks Flat to Edging Higher Pre-Bell Monday

PLRX

MT Newswires

9 months ago

Sector Update: Health Care

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues
PLRX

Benzinga

9 months ago

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues

PLRX

MT Newswires

9 months ago

Wells Fargo Downgrades Pliant Therapeutics to Equalweight From Overweight, $4 Price Target

PLRX

MT Newswires

9 months ago

Citigroup Downgrades Pliant Therapeutics to Neutral From Buy, $4 Price Target

PLRX

MT Newswires

9 months ago

HC Wainwright Downgrades Pliant Therapeutics to Neutral From Buy

PLRX

MT Newswires

9 months ago

Oppenheimer Downgrades Pliant Therapeutics to Perform From Outperform

PLRX

MT Newswires

9 months ago

RBC Downgrades Pliant Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $45, Keeps Speculative Risk

PLRX

MT Newswires

9 months ago

Pliant Therapeutics Suspends Enrollment in Phase 2b Idiopathic Pulmonary Fibrosis Trial

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
PLRX

GlobeNewswire

9 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PLRX

GlobeNewswire

10 months ago

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
PLRX

GlobeNewswire

10 months ago

Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
PLRX

GlobeNewswire

10 months ago

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Pliant Therapeutics to Participate in Upcoming Investor Events
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Pliant Therapeutics to Participate in the Stifel Healthcare Conference
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
PLRX

GuruFocus.com

a year ago

Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
PLRX

GlobeNewswire

a year ago

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

Pliant Therapeutics to Participate in Upcoming Investor Events
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
PLRX

GlobeNewswire

a year ago

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

PLRX

MT Newswires

a year ago

Oppenheimer Adjusts Pliant Therapeutics Price Target to $45 From $48, Maintains Outperform Rating

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
PLRX

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
PLRX

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
PLRX

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
PLRX

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement
PLRX

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
PLRX

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake
PLRX

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

PLRX

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

PLRX

MT Newswires

a year ago

Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
PLRX

GlobeNewswire

a year ago

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
PLRX

Simply Wall St.

2 years ago

Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

PLRX

MT Newswires

2 years ago

Oppenheimer Adjusts Price Target on Pliant Therapeutics to $48 From $47, Maintains Outperform Rating

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

PLRX

MT Newswires

2 years ago

RBC Cuts Price Target on Pliant Therapeutics to $45 From $54, Keeps Outperform, Speculative Risk

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Pliant Therapeutics to Participate in Upcoming Investor Events
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics to Participate in Upcoming Investor Events
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
PLRX

Zacks

2 years ago

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Pliant Therapeutics to Participate in Upcoming Investor Conferences
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Pliant Therapeutics to Participate in Upcoming Investor Events
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
PLRX

GlobeNewswire

2 years ago

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Share on Social Networks: